A quantitative structure-activity relationship analysis on a series of alkyl benzenes metabolized by human cytochrome P450 2E1

Journal of Biochemical and Molecular Toxicology

Volumn 17, Issue 1, 2003, Pages 47-52

  Lewis, David F V ^a   Sams, Craig ^b   Loizou, George D ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b HEALTH AND SAFETY LABORATORY   (United Kingdom)

Author keywords

Alkyl benzenes; Cytochrome P450 2E1; Quantitative structure activity relationships

Indexed keywords

ALKYLBENZENE; CYTOCHROME P450 2E1;

ADULT; AEROBIC METABOLISM; AGED; ARTICLE; BINDING AFFINITY; CALCULATION; CONTROLLED STUDY; DNA TEMPLATE; ELECTRONICS; FEMALE; HUMAN; HUMAN CELL; LIPOPHILICITY; MALE; METABOLIC RATE; MOLECULAR MODEL; QUANTITATIVE ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

AGED; BENZENE DERIVATIVES; BINDING SITES; CYTOCHROME P-450 CYP2E1; FEMALE; HUMANS; HYDROPHOBICITY; KINETICS; MALE; MICROSOMES, LIVER; MIDDLE AGED; MODELS, CHEMICAL; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; THERMODYNAMICS;

EID: 0037247950     PISSN: 10956670     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbt.10055     Document Type: Article

References (18)

1. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997;29:413-580.
2. Ronis MJJ, Lindros KO, Ingelman-Sundberg M. The CYP2E subfamily. In: Ioannides C, editor. Cytochromes P450-Metabolic and Toxicological Aspects. Boca Raton, FL: CRC Press; 1996. Ch. 9, pp 211-239.
3. Guengerich FP, Kim DH, Iwasaki M. Role of human P450IIE1 in the oxidation of several low molecular weight cancer suspects, Chem Res Toxicol 1991;4:168-179.
4. Lewis DFV, Bird MG, Dickins M, Lake BG, Eddershaw PJ, Tarbit MH, Goldfarb PS. Molecular modeling of human CYP2E1 by homology with the CYP102 haemoprotein domain: Investigation of the interactions of substrates and inhibitors within the putative active site of the human CYP2E1 isoform. Xenobiotica 2000;30: 1-25.
5. Lewis DFV, Dickins M. Factors influencing rates and clearance in P450-mediated reactions: QSARs for substrates of the xenobiotic-metabolizing hepatic microsomal P450s. Toxicology 2002;170:45-53.
6. Traylor TG, Xu F. Model reactions related to cytochrome P450. Effects of alkene structure on the rates of epoxide formation. J Am Chem Soc 1988;110:1953-1958.
7. Lewis DFV, Eddershaw PJ, Dickins M, Tarbit MH, Goldfarb PS. Structural determinants of P450 substrate specificity, binding affinity and catalytic rate. Chem-Biol Interact 1998;115:175-199.
8. Yin H, Anders MW, Korzekwa KR, Higgins L, Thummel KE, Kharasch ED, Jones JP. Designing safer chemicals: Predicting the rates of metabolism of halogenated alkanes. Proc Natl Acad Sci USA 1995;92:11076-11080.
9. Jones JP, Mysinger M, Korzekwa KR. Computational models for cytochrome P450: A predictive electronic model for aromatic oxidation and hydrogen atom abstraction. Drug Metab Dispos 2002;30:7-12.
10. Dewar MJS, Zoebisch EG, Kealy EF Stewart JJP. AM1: A new general purpose quantum mechanical molecular model. J Am Chem Soc 1985;107:3902-3909.
11. Lewis DFV. Homology modeling of CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 2002;32:305-323.
12. Chauret N, Annick G, Nicoll-Griffith DA. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 1998;26:1-4.
13. Tassaneeyakul W, Birkett DJ, Edwards JW, Veronese ME, Tassaneeyakul W, Tukey RH, Miners JO. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene, o-, m- and p-xylene. J Pharmacol Exp Ther 1996;273:101-108.
14. Nakajima T, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, Aoyama T. Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem Res Toxicol 1994;7:891-896.
15. Mendrala AL, Langvardt PW, Nitschke KD, Quast JF, Nolan RJ. In vitro kinetics of styrene and styrene oxide metabolism in rat, mouse and human. Arch Toxicol 1993;67:18-27.
16. Carlson GP, Mantick NA, Powley MW. Metabolism of styrene by human liver and lung. J Toxicol Environ Health 2000;59:591-595.
17. Csanady GA, Mendrala AL, Nolan RJ, Filser JG. A physiological pharmacokinetic model for styrene and styrene-7,8-oxide in mouse, rat and man. Arch Toxicol 1994;68:143-157.
18. Wenker MAM, Kezic S, Monster AC, De Wolff FA. Metabolism of styrene in the human liver in vitro: Interindividual variation and enantioselectivity. Xenobiotica 2001;31:61-72.